Last reviewed · How we verify

NCT06800456

The Role of Cyberchondria Severity in the Relationship Between HPV Awareness and Vaccination Attitudes in Adult Women

Completed Last updated 30 January 2025
What this trial tests

trial in Human Papillomavirus Infection in 337 participants. Completed in 1 December 2024.

Timeline
1 June 2024
Primary endpoint
1 December 2024
1 December 2024

Quick facts

Lead sponsorAcibadem University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment337
Start date1 June 2024
Primary completion1 December 2024
Estimated completion1 December 2024
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Acibadem University

Who can join

Adults 18 to 49, female only, with Human Papillomavirus Infection or HPV Vaccines. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Human papillomavirus (HPV) is a prevalent sexually transmitted infection linked to nearly all cases (99%) of cervical cancer. Prophylactic HPV vaccination is effective in preventing these cancers, complemented by HPV screening and treatment of precancerous lesions. The World Health Organization (WHO) aims to eliminate cervical cancer by 2030 through focused efforts on vaccination, diagnosis, and treatment. Primary prevention strategies include reducing sexual risk factors and administering prophylactic vaccines. Despite awareness of HPV testing, many women lack understanding of its importance and fail to follow through with screenings and necessary treatments. Overall societal awareness of HPV remains inadequate. Studies reveal disparities in HPV vaccine awareness: while 60.7% of women have heard of the vaccine, only 1% have received it. Awareness varies widely across regions, with Turkey reporting rates from 3.8% to 57%, and vaccine awareness ranging from 2.2% to 74.7% (Özdemir et al., 2020). In the UK, concerns over potential negative results lead many women to defer HPV testing. Health anxiety, defined as interpreting minor symptoms as serious health issues, drives individuals to seek excessive online health information, a phenomenon known as cyberchondria. Studies link cyberchondria with heightened health anxiety, exacerbated by prolonged internet searches. Barriers to HPV screening and vaccination include fear of side effects, lack of information, cost concerns, and anxiety over potential outcomes. While women testing positive for HPV show higher levels of cyberchondria, no direct correlation has been established between cyberchondria severity and HPV awareness or vaccination attitudes in adult women. This summary encapsulates the key findings and insights from the referenced studies on HPV, vaccination, and health anxiety.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Role of cyberchondria severity in the relationship between HPV awareness and vaccination status among adult women.
    Coşkun M, Ünlü Suvari G, Özdemir İN. · · 2025 · PMID 41408614 · DOI 10.1186/s12889-025-25938-5

Verify or expand the search:

Other recruiting trials for Human Papillomavirus Infection

Currently open trials in the same condition.

Other Acibadem University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06800456.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing